Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.

Biotechnology

Edgewise Therapeutics

Edgewise Therapeutics' headquarters in Boulder, CO, United States

Kevin Koch

John Moore

Chris Dufton

Ryan Waite

Joanne Donovan

Maureen Franco

Zhou Jiang

Sherri Norland

Nicole Rempel Kilburn

Mike Carruthers

Maria Mancini

Ericka Benson

Bruce D. Johnson

Badreddin Edris

Abby Bronson

Description

People (21)

Kevin Koch

Bruce D. Johnson

Jonathan Lane

Angela Peter

Ben Barthel

Breanne Newell-Stamper

Emily DiNatale

Lindsey Lee

Molly Madden

Sara Cantrell

Sarah Lehman

Stephen Schlachter

Ying Qian

Janet Hill

Jane Platt

Nicole Rempel Kilburn

Sherri Norland

Nastassia Medrano

Brooke Harrison

Laura Emery

Marcus Henze

Jobs